Inflammatory bowel disease (IBD), in particular Crohn's disease refractory to conventional
therapy, fistulizing Crohn's disease and chronic active ulcerative colitis, generally respond …

Background Anti‐TNF agents are now widely used in Crohn's disease (CD), and in
ulcerative colitis (UC). Aim To review the safety profile of anti‐TNF agents in all patients …

Background Anti‐tumour necrosis factor‐α (TNF α) antibodies are efficacious in
inflammatory bowel disease (IBD). These drugs carry the theoretical risk of malignancy …

Anti-tumour necrosis factor-alpha (TNF-a) agents have changed the way of treating
inflammatory bowel diseases (IBD) refractory to conventional medications (corticosteroids …

In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era
for inflammatory bowel disease, leading to marked improvements in treatment options and …

Tumour necrosis factor alpha (TNF-alpha) inhibitors ensure valuable treatment advantages
for patients with inflammatory bowel diseases (IBD) by offering a more targeted anti …

The use of anti-tumor necrosis factor-α therapy for inflammatory bowel disease represents
the most important advance in the care of these patients since the publication of the National …

BACKGROUND & AIMS: Although anti–tumor necrosis factor (TNF) therapy can effectively
treat Crohn's disease (CD), there is concern that it might increase the risk of non-Hodgkin's …

Antitumor necrosis factor α (anti-TNF) agents have dramatically influenced management of
refractory inflammatory bowel disease (IBD). However, not all patients respond to treatment …

Anti-tumour necrosis factor (TNF) antibodies have been widely used for approximately 25
years now. The first clinical observations in patients with refractory Crohn's disease rapidly …